Though characteristics of cell line cells are not identical to parental tumor cells, revealed insufficient or absence of EpCAM on the plasma membrane may partially account for the ineffective detection of CTCs by anti-EpCAM-dependent strategies in most NSCLC and pancreatic cancer as well as many other types of cancer patients. This evidence concerns the gene EPCAM and non-small cell lung carcinoma.